Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.68% | 165.04% | 371.23% | 70.98% | 222.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.76% | 4.62% | 23.51% | -2.11% | 131.60% |
| Operating Income | 29.76% | -4.62% | -23.51% | 2.11% | -131.60% |
| Income Before Tax | 42.75% | -0.25% | 159.74% | -127.96% | -192.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.75% | -0.25% | 159.74% | -127.96% | -192.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.75% | -0.25% | 159.74% | -127.96% | -192.05% |
| EBIT | 29.76% | -4.62% | -23.51% | 2.11% | -131.60% |
| EBITDA | 29.83% | -4.64% | -23.58% | 2.12% | -132.28% |
| EPS Basic | 84.29% | 72.47% | 118.65% | -127.71% | -623.42% |
| Normalized Basic EPS | 84.29% | 72.47% | 118.65% | -127.73% | -623.38% |
| EPS Diluted | 84.30% | 72.45% | 62.94% | -127.71% | -624.04% |
| Normalized Diluted EPS | 84.29% | 72.47% | 118.19% | -127.73% | -623.38% |
| Average Basic Shares Outstanding | 264.33% | 264.19% | 220.28% | 0.11% | -59.63% |
| Average Diluted Shares Outstanding | 264.33% | 264.19% | 228.38% | 0.11% | -59.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |